These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15338953)

  • 1. Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).
    Singh J; Ling LE; Sawyer JS; Lee WC; Zhang F; Yingling JM
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):437-45. PubMed ID: 15338953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
    Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent.
    Zúñiga JE; Groppe JC; Cui Y; Hinck CS; Contreras-Shannon V; Pakhomova ON; Yang J; Tang Y; Mendoza V; López-Casillas F; Sun L; Hinck AP
    J Mol Biol; 2005 Dec; 354(5):1052-68. PubMed ID: 16289576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactome of transforming growth factor-beta type I receptor (TbetaRI): inhibition of TGFbeta signaling by Epac1.
    Conrotto P; Yakymovych I; Yakymovych M; Souchelnytskyi S
    J Proteome Res; 2007 Jan; 6(1):287-97. PubMed ID: 17203972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
    Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
    Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of mice with conditionally activated transforming growth factor beta signaling through the TbetaRI/ALK5 receptor.
    Bartholin L; Cyprian FS; Vincent D; Garcia CN; Martel S; Horvat B; Berthet C; Goddard-Léon S; Treilleux I; Rimokh R; Marie JC
    Genesis; 2008 Dec; 46(12):724-31. PubMed ID: 18821589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of TGF-beta in cancer and the potential for therapy and prevention.
    Kaklamani VG; Pasche B
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):649-61. PubMed ID: 15270668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered primordial germ cell migration in the absence of transforming growth factor beta signaling via ALK5.
    Chuva de Sousa Lopes SM; van den Driesche S; Carvalho RL; Larsson J; Eggen B; Surani MA; Mummery CL
    Dev Biol; 2005 Aug; 284(1):194-203. PubMed ID: 15993878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFbeta receptors in mice.
    Carvalho RL; Itoh F; Goumans MJ; Lebrin F; Kato M; Takahashi S; Ema M; Itoh S; van Rooijen M; Bertolino P; Ten Dijke P; Mummery CL
    J Cell Sci; 2007 Dec; 120(Pt 24):4269-77. PubMed ID: 18029401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.
    Yoo YA; Kang MH; Kim JS; Oh SC
    Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor.
    De Crescenzo G; Hinck CS; Shu Z; Zúñiga J; Yang J; Tang Y; Baardsnes J; Mendoza V; Sun L; López-Casillas F; O'Connor-McCourt M; Hinck AP
    J Mol Biol; 2006 Jan; 355(1):47-62. PubMed ID: 16300789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-{beta}1 activates two distinct type I receptors in neurons: implications for neuronal NF-{kappa}B signaling.
    König HG; Kögel D; Rami A; Prehn JH
    J Cell Biol; 2005 Mar; 168(7):1077-86. PubMed ID: 15781474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
    Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
    J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic analyses facilitate identification of receptors and signalling pathways for growth differentiation factor 9 and related orphan bone morphogenetic protein/growth differentiation factor ligands.
    Mazerbourg S; Hsueh AJ
    Hum Reprod Update; 2006; 12(4):373-83. PubMed ID: 16603567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting TGFbeta-mediated processes in cancer.
    Romano MF
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):253-63. PubMed ID: 19333871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.
    Laping NJ; Everitt JI; Frazier KS; Burgert M; Portis MJ; Cadacio C; Gold LI; Walker CL
    Clin Cancer Res; 2007 May; 13(10):3087-99. PubMed ID: 17505012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.